CAJ | 학술논문

目的：：探讨瑞舒伐他汀对急性冠脉综合征( acute coronary syndrome,ACS)患者炎症因子和细胞因子的影响。方法：将168例ACS患者随机分为三组,阿托伐他汀20 mg组56例、瑞舒伐他汀10 mg组56例和瑞舒伐他汀20 mg组56例,对比各组治疗前后血清中炎症因子和细胞因子水平,并观察心血管事件(再发心绞痛、非致死性心肌梗死和心源性死亡)发生率。结果：与治疗前相比,三组患者治疗后在超敏C反应蛋白(hs-CRP)、血清肿瘤坏死因子-a(TNF-a)和白细胞介素6(IL-6)水平方面均明显低于治疗前(均P<0.05),且瑞舒伐他汀20 mg组显著低于其他两组(均P<0.05)；三组患者在细胞因子VEGF和VCAM-1水平方面均显著降低(均P<0.05),且瑞舒伐他汀20 mg组显著低于其他两组(均P<0.05)；三组患者治疗后心血管事件发生率没有明显差异(P>0.05)。结论： ACS患者服用瑞舒伐他汀可降低炎症因子和细胞因子的水平,减轻炎症反应并能稳定动脉粥样斑块,且这种作用与剂量正相关,对改善ACS患者的病情有益。
목적：：탐토서서벌타정대급성관맥종합정( acute coronary syndrome,ACS)환자염증인자화세포인자적영향。방법：장168례ACS환자수궤분위삼조,아탁벌타정20 mg조56례、서서벌타정10 mg조56례화서서벌타정20 mg조56례,대비각조치료전후혈청중염증인자화세포인자수평,병관찰심혈관사건(재발심교통、비치사성심기경사화심원성사망)발생솔。결과：여치료전상비,삼조환자치료후재초민C반응단백(hs-CRP)、혈청종류배사인자-a(TNF-a)화백세포개소6(IL-6)수평방면균명현저우치료전(균P<0.05),차서서벌타정20 mg조현저저우기타량조(균P<0.05)；삼조환자재세포인자VEGF화VCAM-1수평방면균현저강저(균P<0.05),차서서벌타정20 mg조현저저우기타량조(균P<0.05)；삼조환자치료후심혈관사건발생솔몰유명현차이(P>0.05)。결론： ACS환자복용서서벌타정가강저염증인자화세포인자적수평,감경염증반응병능은정동맥죽양반괴,차저충작용여제량정상관,대개선ACS환자적병정유익。
Objective:To explore the clinical effect of rosuvastatin on inflammatory factors and cytokines in patients with acute coronary syndrome (ACS). Methods:168 cases of ACS were divided into Atorvastatin (56 cases),rosuvastatin 10 mg group (56 ca-ses) and 20 mg group (56 cases). The plasma levels of inflammatory factors and cytokines were measured,and the occurrence rate of cardiovascular events were observed. Results:The levels of hs-CRP,TNF-a,and IL-6 in 20 mg group and in 10 mg group were signifi-cantly lower than those before treatment (P<0. 05),and it was the lowest in 20 mg group among three groups. Besides,the levels of VEGF and VCAM-1 in 20 mg group and 10 mg group were also significantly lower. The incidence of serious cardiovascular events in three groups had no difference after the treatment. Conclusion:Rosuvastatin can decrease the plasma levels of inflammatory factors and cytokines,reducing inflammation and stabilizing atherosclerotic plaque,thereby,reducing the incidence of serious cardiovascular event, and improving the situation of patients with ACS.